Endevica Bio
Endevica Bio is committed to pioneering science-driven solutions in peptide therapeutics, focusing on treatments for cachexia, obesity, and metabolic disorders. The company develops first-in-class peptide drug candidates that target complex conditions with innovative approaches, aiming to transform patient outcomes and address unmet medical needs.
Industries
Nr. of Employees
small (1-50)
Endevica Bio
Patents
Products
CNS-penetrant peptide candidate for prevention of cancer-related weight loss (melanocortin‑3/4 antagonist)
Clinical-stage peptide therapeutic designed to cross the blood–brain barrier and modulate central melanocortin pathways to prevent chemotherapy- and disease-associated weight loss and preserve lean mass; completed Phase 1 and entered Phase 2 clinical testing in metastatic colorectal cancer patients.
Orally dosed peptide candidate for obesity and weight modulation (melanocortin receptor agonist)
Preclinical oral peptide agonist targeting central melanocortin pathways shown in animal studies to induce durable weight loss, reduce caloric intake, and preserve muscle mass; non-human primate and rodent efficacy data reported.
TCMCB07
A peptide drug developed by Endevica Bio to treat cachexia, showing promising results in a Phase 1 study.
TCMCB07 (B07)
An experimental melanocortin‐3/4 antagonist peptide drug candidate in clinical development for the treatment of cachexia, designed to cross the blood-brain barrier and modulate the body's behavioral and metabolic response to chronic illness.
mifomelatide
A dual MC3R/MC4R antagonist in Phase 2 clinical development to prevent and treat cachexia in patients with advanced cancer, improving appetite, stabilizing body weight, and preserving muscle and fat mass.
710GO
An oral dual melanocortin-3 and -4 receptor (MC3R/MC4R) agonist designed to activate the melanocortin system to induce higher quality, durable weight loss without lean body mass loss and other side effects common with GLP-1 receptor agonists.
CNS-penetrant peptide candidate for prevention of cancer-related weight loss (melanocortin‑3/4 antagonist)
Clinical-stage peptide therapeutic designed to cross the blood–brain barrier and modulate central melanocortin pathways to prevent chemotherapy- and disease-associated weight loss and preserve lean mass; completed Phase 1 and entered Phase 2 clinical testing in metastatic colorectal cancer patients.
Orally dosed peptide candidate for obesity and weight modulation (melanocortin receptor agonist)
Preclinical oral peptide agonist targeting central melanocortin pathways shown in animal studies to induce durable weight loss, reduce caloric intake, and preserve muscle mass; non-human primate and rodent efficacy data reported.
TCMCB07
A peptide drug developed by Endevica Bio to treat cachexia, showing promising results in a Phase 1 study.
TCMCB07 (B07)
An experimental melanocortin‐3/4 antagonist peptide drug candidate in clinical development for the treatment of cachexia, designed to cross the blood-brain barrier and modulate the body's behavioral and metabolic response to chronic illness.
mifomelatide
A dual MC3R/MC4R antagonist in Phase 2 clinical development to prevent and treat cachexia in patients with advanced cancer, improving appetite, stabilizing body weight, and preserving muscle and fat mass.
710GO
An oral dual melanocortin-3 and -4 receptor (MC3R/MC4R) agonist designed to activate the melanocortin system to induce higher quality, durable weight loss without lean body mass loss and other side effects common with GLP-1 receptor agonists.
Services
Design and conduct of first-in-human and multi-site Phase 2 clinical studies for peptide therapeutics, including regulatory interactions and CRO partnerships.
Design and conduct of first-in-human and multi-site Phase 2 clinical studies for peptide therapeutics, including regulatory interactions and CRO partnerships.
Expertise Areas
- Peptide therapeutics
- Central nervous system (CNS)–targeted drug design
- Cachexia drug development
- Obesity and metabolic disorder therapeutics
Key Technologies
- Peptidomimetics and peptide engineering
- Blood–brain barrier penetration strategies
- Melanocortin receptor modulation (MC3/4 targeting)
- Oral peptide delivery/formulation